An interventional study of Teprenone and Esomeprazole in Hematopoietic Stem Cell Transplantation (HSCT), aGVHD and Infection, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to observe whether different gastric protection strategies affect the incidence of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Proton pump inhibitors (PPIs) are routinely used for gastric protection during transplantation, but their prolonged use may suppress gastric acid, alter gut microbiota, and potentially increase the risk of aGVHD. Teprenone, a gastric mucosal protective agent (GMPA), enhances mucosal defense mechanisms including promoting mucus secretion, increasing gastric mucosal blood flow, and facilitating epithelial cell repair, without affecting gastric acid secretion, and may therefore preserve microbial diversity and modify aGVHD risk. This study compares two strategies: continuous PPI use versus switching from PPIs to teprenone after transplantation.
The main questions this study aims to answer are:
In this prospective, randomized, parallel-controlled, single-center trial, approximately 198 patients undergoing allo-HSCT will be enrolled and assigned in a 1:1 ratio using a central randomization system. The experimental group (teprenone group) will receive standard-dose PPIs (esomeprazole, 40 mg/d, intravenous/oral) during conditioning and switch to teprenone (50 mg tid, orally) after transplantation through day +100. The control group (PPI group) will receive continuous standard-dose PPIs from conditioning through day +100. Probiotic use is prohibited from conditioning through day +100 in both groups. All other anti-infective, GVHD prophylaxis, and supportive care regimens are identical between the two groups.
The primary endpoint of this study is the cumulative incidence of aGVHD within +100 days post-transplantation. Secondary endpoints include grade II-IV and grade III-IV aGVHD, lower gastrointestinal aGVHD, steroid-refractory aGVHD, gut and salivary microbiome dynamics (α-diversity, β-diversity, and specific taxa at pre-conditioning, day 0, day +14, and day +28), plasma biomarkers related to intestinal barrier integrity, systemic inflammation, and immune regulation , infectious and gastrointestinal complications (febrile neutropenia, diarrhea, C. difficile infection, bacteremia, EBV/CMV reactivation, upper GI bleeding, reflux), and 1-year survival outcomes (non-relapse mortality, overall survival, GVHD-free/relapse-free survival).
During the study, participants will:
2,096 studies on the registry are indexed under Infections; 362 are open to participants now.
This study's planned enrollment of 198 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive standard-dose proton pump inhibitor (PPI) during the conditioning phase. After transplantation, they will switch to teprenone, a gastric mucosal protective agent, at a dose of 50 mg three times daily (tid), administered orally, from the day of stem cell infusion through day +100 post-transplantation.
Drug: Teprenone
Participants in this arm will receive continuous standard-dose proton pump inhibitor (PPI) therapy with esomeprazole at 40 mg daily, administered either intravenously or orally, from the start of conditioning through day +100 post-transplantation.
Drug: Esomeprazole
Teprenone acts by enhancing gastric mucosal defense mechanisms, including promoting mucus secretion, increasing gastric mucosal blood flow, and facilitating epithelial cell repair, without affecting gastric acid secretion. The switch from PPI to teprenone is intended to maintain gastric protection while potentially preserving gut microbial diversity and reducing the risk of acute graft-versus-host disease (aGVHD).
Continuous PPI use suppresses gastric acid secretion throughout the peri-transplantation period, which may alter gut microbiota composition and potentially influence aGVHD risk.
Incidence of acute graft-versus-host disease (aGVHD) post-transplantation
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of grade II-IV acute graft-versus-host disease (aGVHD)
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of grade III-IV acute graft-versus-host disease (aGVHD)
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of lower gastrointestinal aGVHD
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Oral microbiome diversity and composition
Time frame: At pre-conditioning, Day +0, Day +14, and Day +28 post-transplantation
Fecal microbiome diversity and composition
Time frame: At pre-conditioning, Day +0, Day +14, and Day +28 post-transplantation
Incidence of febrile neutropenia
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of diarrhea
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of Clostridioides difficile infection
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up
Incidence of enterococcal colonization/infection
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of bacteremia
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of upper gastrointestinal bleeding
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
Incidence of clinically significant reflux symptoms
Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first
1-year non-relapse mortality (NRM)
Time frame: From Day 0 to 1 year post-transplantation
1-year overall survival (OS)
Time frame: From Day 0 to 1 year post-transplantation
1-year GVHD-free, relapse-free survival (GRFS)
Time frame: From Day 0 to 1 year post-transplantation
Plan to share: Undecided
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
Of 276 non-industry interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 51. This study's planned 24 months is close to that.
Counting every sponsor, half of 307 studies reached it within 24 months; a quarter within 9 and three quarters within 50.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Geranylgeranylacetone
First Affiliated Hospital of Zhejiang University →